Wells Fargo
CYT

Wells Fargo’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Wells Fargo’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-147
Closed -$447 – 7770
2023
Q4 		$447 Buy
147
+8
+6% +$24 ﹤0.01% 6412
2023
Q3 		$395 Buy
139
+37
+36% +$102 ﹤0.01% 6413
2023
Q2 		$265 Buy
102
+4
+4% +$8 ﹤0.01% 6622
2023
Q1 		$178 Buy
98
+1
+1% +$2 ﹤0.01% 6803
2022
Q4 		$160 Buy
97
+3
+3% +$5 ﹤0.01% 6692
2022
Q3 		$0 Buy
94
+44
+88% +$115 ﹤0.01% 7634
2022
Q2 		$0 Sell
50
-3,511
-99% -$8.97K ﹤0.01% 7748
2022
Q1 		$13K Sell
3,561
-875
-20% -$4.98K ﹤0.01% 6187
2021
Q4 		$50K Buy
4,436
+4,393
+10,216% +$67K ﹤0.01% 5965
2021
Q3 		$1K Buy
+43
New +$804 ﹤0.01% 6843

Other funds holding CYT

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return

Wells Fargo's CYT Position: Q1 2024 in Review

Wells Fargo sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q1 2024, closing a stake of 147 shares — an estimated $447 sold.

Wells Fargo first reported a position in CYT in Q3 2021 and held it in 10 quarters. The position peaked at $50K in Q4 2021. 4 funds tracked by Wall St. Rank hold CYT as of Q1 2024.

  • Wells Fargo reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Wells Fargo sold 147 Cyteir Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $447.
  • Wells Fargo first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q3 2021 and held it in 10 quarters.
  • Wells Fargo's Cyteir Therapeutics, Inc. Common Stock position peaked at $50K in Q4 2021.
  • 4 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Wells Fargo's 13F filing for Q1 2024, filed 10 May 2024.